Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Topical, nasal and ophthalmic antihistamine.
According to the manufacturer, plasma concentrations achieved after nasal or ophthalmic administration are very low and are eliminated in breast milk in clinically insignificant amounts, 0.3-0.6% of the maternal dose: 1.5 to 3 micrograms. (AEMPS 2021 and 2020, J&J 2010)
As with most topical ophthalmic and nasal preparations, the tiny dose and its low passage into the bloodstream make it compatible with breastfeeding.